News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,380 Results
Type
Article (14947)
Company Profile (299)
Press Release (267129)
Multimedia
Podcasts (80)
Webinars (11)
Section
Business (79854)
Career Advice (163)
Deals (13340)
Drug Delivery (39)
Drug Development (50714)
Employer Resources (31)
FDA (5846)
Job Trends (5170)
News (145120)
Policy (10077)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (922)
Accelerated approval (21)
Adcomms (14)
Allergies (88)
Alliances (21761)
ALS (130)
Alzheimer's disease (1045)
Antibody-drug conjugate (ADC) (252)
Approvals (6047)
Artificial intelligence (276)
Autoimmune disease (124)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (105)
Biotechnology (230)
Bladder cancer (103)
Brain cancer (47)
Breast cancer (351)
Cancer (3218)
Cardiovascular disease (246)
Career advice (148)
Career pathing (8)
CAR-T (225)
CDC (5)
Cell therapy (581)
Cervical cancer (15)
Clinical research (43797)
Collaboration (1186)
Company closure (2)
Compensation (614)
Complete response letters (43)
COVID-19 (1103)
CRISPR (91)
C-suite (581)
Cystic fibrosis (112)
Data (4443)
Denatured (16)
Depression (98)
Diabetes (258)
Diagnostics (1387)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (201)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (222)
Earnings (31750)
Editorial (28)
Employer branding (4)
Employer resources (29)
Events (51865)
Executive appointments (634)
FDA (7646)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1006)
Gene editing (189)
Generative AI (23)
Gene therapy (502)
GLP-1 (510)
Government (1153)
Grass and pollen (3)
Guidances (166)
Healthcare (6618)
HIV (19)
Huntington's disease (44)
IgA nephropathy (76)
Immunology and inflammation (197)
Immuno-oncology (48)
Indications (80)
Infectious disease (1218)
Inflammatory bowel disease (162)
Inflation Reduction Act (10)
Influenza (43)
Intellectual property (172)
Interviews (18)
IPO (7348)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (24)
Layoffs (244)
Leadership (10)
Legal (1402)
Liver cancer (41)
Longevity (12)
Lung cancer (432)
Lymphoma (255)
Machine learning (24)
Management (7)
Manufacturing (388)
MASH (134)
Medical device (2667)
Medtech (2676)
Mergers & acquisitions (6626)
Metabolic disorders (742)
Multiple sclerosis (107)
NASH (13)
Neurodegenerative disease (242)
Neuropsychiatric disorders (70)
Neuroscience (2000)
Neurotech (1)
NextGen: Class of 2026 (2035)
Non-profit (867)
Now hiring (31)
Obesity (339)
Opinion (126)
Ovarian cancer (132)
Pain (104)
Pancreatic cancer (167)
Parkinson's disease (239)
Partnered (12)
Patents (317)
Patient recruitment (353)
Peanut (45)
People (26735)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15522)
Phase 2 (20354)
Phase 3 (12848)
Pipeline (3521)
Policy (95)
Postmarket research (853)
Preclinical (6550)
Press Release (30)
Prostate cancer (154)
Psychedelics (50)
Radiopharmaceuticals (242)
Rare diseases (682)
Real estate (1449)
Recruiting (12)
Regulatory (9983)
Reports (20)
Research institute (975)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (18)
Schizophrenia (127)
Series A (190)
Series B (141)
Service/supplier (1)
Sickle cell disease (82)
Special edition (19)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2007)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (346)
Venture capital (70)
Weight loss (174)
Women's health (30)
Worklife (2)
Date
Today (97)
Last 7 days (383)
Last 30 days (1390)
Last 365 days (17821)
2026 (2438)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26823)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11743)
2017 (13745)
2016 (11841)
2015 (14351)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7615)
2010 (7428)
Location
Africa (154)
Alabama (66)
Alaska (2)
Arizona (72)
Arkansas (6)
Asia (18291)
Australia (3120)
California (7245)
Canada (1882)
China (790)
Colorado (252)
Connecticut (260)
Delaware (240)
Europe (39282)
Florida (929)
Georgia (212)
Hawaii (2)
Idaho (17)
Illinois (403)
India (37)
Indiana (167)
Iowa (8)
Japan (234)
Kansas (81)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (754)
Massachusetts (5720)
Michigan (110)
Minnesota (252)
Mississippi (3)
Missouri (33)
Montana (16)
Nebraska (5)
Nevada (34)
New Hampshire (21)
New Jersey (1688)
New Mexico (13)
New York (1798)
North Carolina (848)
North Dakota (6)
Northern California (3575)
Ohio (181)
Oklahoma (11)
Oregon (24)
Pennsylvania (1313)
Puerto Rico (9)
Rhode Island (26)
South America (215)
South Carolina (10)
Southern California (2877)
Tennessee (41)
Texas (934)
United States (23902)
Utah (98)
Virginia (141)
Washington D.C. (37)
Washington State (600)
West Virginia (1)
Wisconsin (47)
282,380 Results for "nektar therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Autoimmune disease
Nektar Digs Into Mid-Stage Data to Establish Alopecia Efficacy of Rezpeg
Despite falling short of its primary Phase II objective, Nektar plans to push its T cell stimulator rezpeg into Phase III development.
December 17, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking
Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma’s partnership with Nektar over atopic dermatitis therapy rezpeg.
October 20, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
February 12, 2026
·
6 min read
Immunology and inflammation
Nektar’s Rezpeg Differentiates in Atopic Dermatitis With Durable, Deep Responses in Mid-Stage
The percentage of patients achieving total clearance of eczema lesions in a Phase 2b trial increased with prolonged rezpeg treatment.
February 11, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Nektar Provides More Data for Dermatitis Drug, but Key Questions Remain Unanswered
Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to analysts at William Blair.
September 19, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 15, 2026
·
3 min read
Press Releases
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
February 17, 2026
·
8 min read
Press Releases
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
November 6, 2025
·
13 min read
Press Releases
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 in London
October 31, 2025
·
1 min read
Press Releases
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
December 8, 2025
·
5 min read
1 of 28,238
Next
